Kamada Ltd. have announced that favorable results from a preclinical study analyzing the effects of the Company’s human Alpha-1 Antitrypsin (AAT), Glassia, in inter-species islet graft transplantation were published in PLOS One
Product development firm Cambridge Consultants (Cambridge, MA) recently announced that it is working with the Institute of Metabolic Science (IMS) at Addenbrooke’s Hospital in Cambridge, UK on groundbreaking research to create an artificial pancreas.
A cure may not be around the corner, but scientists are hard at work on ways to replicate the functions of the pancreas. Researchers are using rodents to develop a system for targeted non-user initiated insulin delivery.
Medtronic Inc. (MDT) insulin pump designed to temporarily shut off was able to reduce the incidence of a potentially fatal condition that occurs when blood-sugar levels fall too low–a key advance in the effort to fully automate the delivery of insulin in diabetes patients.
Scientists are working to create an artificial pancreas that will help reduce the complications of type 1 diabetes and significantly improve the lives and life expectancy of millions of patients with the condition.
Scientists have found a way to make insulin-producing cells multiply in the laboratory. This may allow clinicians to treat more patients who have type 1 diabetes with transplants of the cells
You might ask, isn’t an artificial pancreas basically a marriage of an insulin pump and continuous glucose monitor (CGM)? What’s the difference anyway?
University of Missouri scientist Habib Zaghouani, PhD, is developing a potential cure for type 1 diabetes by combining adult stem cells with a promising new drug he developed at MU
University of Missouri scientist Habib Zaghouani, Ph.D., is developing a potential cure for type 1 diabetes by combining adult stem cells with a promising new drug he developed at MU.
A retrospective cohort study was recently published in the journal, Nephrology Dialysis Transplantation, focusing on the mortality rates of patients receiving a pancreas transplant compared to those who were on the waiting list with similar co-morbidities.
After more than three decades of research, a consortium of schools that includes the U has completed testing on the transplant technique.
At last week’s Capital Hill summit on Insulin Independence, researchers from around the world shared a vision of using a combination of therapies built on these same principles to bring perfect blood sugars to those living with type 1 diabetes.
Two weeks ago today for Spring Break I was in gorgeous, palm-studded Santa Barbara, CA. And what does a diabetes technology geek like me do on vacation? Visit the local research clinic, of course!
Now a new generation of medical research and engineering has brought health care closer to a long-sought goal: small implantable devices that continuously monitor blood-sugar levels
Can Type 2 or Type 1 diabetes be not only reversed, but cured? Can beta cells start producing enough insulin? Can the liver store glucose better, and can body cells learn to handle glucose more efficiently?
A new bioengineered, miniature organ dubbed the BioHub might one day offer people with type 1 diabetes freedom from their disease.
Animas Corporation has announced positive results from the second phase of human clinical trials of a first-generation, closed-loop insulin delivery system.
By next year, the modest lab in San Diego hopes to begin human trials for a treatment that could essentially cure type 1 diabetes.
The artificial pancreas — a treatment that’s been called the closest thing to a possible cure for type 1 diabetes — may be another step closer to becoming a reality.
For patients with type 1 diabetes, a dual-hormone artificial pancreas system (also known as a closed-loop delivery system) improved the control of glucose levels and reduced the risk of hypoglycemia compared with conventional pump treatment .